Symtuza is an antiviral medicine used to treat human immunodeficiency virus type 1 (HIV\-1\) in adults and adolescents aged from 12 years (and weighing at least 40 kg). HIV\-1 is a virus that causes acquired immune deficiency syndrome (AIDS). Symtuza contains the active substances darunavir, cobicistat, emtricitabine and tenofovir alafenamide.
Therapeutic Indication
Symtuza is indicated for the treatment of human immunodeficiency virus type 1 (HIV?1\) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg). Genotypic testing should guide the use of Symtuza.
Therapeutic Area (MeSH)
ATC Code
J05AR22
ATC Item
N/A
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| darunavir | N/A | darunavir |
| cobicistat | N/A | cobicistat |
| emtricitabine | N/A | emtricitabine |
| tenofovir alafenamide | N/A | tenofovir alafenamide |
EMA Name
Symtuza
Medicine Name
Symtuza
Aliases
N/ANo risk management plan link.
